LIVIVO - Search results -

Search results

Result 1 - 10 of total 48

Search options

Article ; Online: Thoracic irradiation as consolidation therapy in patients with extensive-stage small cell lung cancer.

Berta, Judit / Rózsás, Anita / Megyesfalvi, Zsolt / Ostoros, Gyula / Döme, Balázs

2022 Volume 35, Issue 1, Page(s) 54–60

Abstract: Purpose of review: Small cell lung cancer (SCLC) is marked by an exceptionally high proliferative rate and poor prognosis. Given its high propensity to metastasize, nearly two-thirds of SCLC patients are diagnosed with extensive-stage (ES) disease when ... ...

Abstract	Purpose of review: Small cell lung cancer (SCLC) is marked by an exceptionally high proliferative rate and poor prognosis. Given its high propensity to metastasize, nearly two-thirds of SCLC patients are diagnosed with extensive-stage (ES) disease when surgery is not a treatment option anymore. Over several decades, only minimal changes have been made in the therapeutic armamentarium of ES-SCLC. Recently, however, several new therapeutic avenues were defined, thus renewing the hope for patients with this recalcitrant cancer. Here, we present an overview of the most current therapeutic advances in ES-SCLC focusing in particular on consolidative thoracic radiation therapy (cTRT) and chemo-immunotherapy. Recent findings: The incorporation of immunotherapy in the standard-of-care of ES-SCLC patients and the resulting outcomes are both a remarkable hallmark of progress and a disappointment. Indeed, chemo-immunotherapy with or without cTRT and prophylactic cranial irradiation contributes to longer survival outcomes with minimal toxicity rates in well selected and properly monitored patients. Nevertheless, the gain in overall survival is still modest relative to that seen in many other solid tumors. Summary: Despite the encouraging results, further clinical trials are needed to determine the efficacy and safety of these therapeutic approaches, and moreover, to identify new predictive biomarkers of response.
MeSH term(s)	Humans ; Small Cell Lung Carcinoma/radiotherapy ; Consolidation Chemotherapy ; Lung Neoplasms/radiotherapy
Language	English
Publishing date	2022-11-16
Publishing country	United States
Document type	Review ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1049384-0
ISSN	1531-703X ; 1040-8746
ISSN (online)	1531-703X
ISSN	1040-8746
DOI	10.1097/CCO.0000000000000911
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3046: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Potential subtype-specific therapeutic approaches in small cell lung cancer.

Horvath, Lilla / Lang, Christian / Boettiger, Kristiina / Aigner, Clemens / Dome, Balazs / Megyesfalvi, Zsolt

Current opinion in oncology

2023 Volume 36, Issue 1, Page(s) 51–56

Abstract: Purpose of review: Small cell lung cancer (SCLC) remains one of the most aggressive thoracic malignancies with an especially dismal prognosis. While the detection of various targetable driver mutations and immune checkpoints have revolutionized the ... ...

Abstract	Purpose of review: Small cell lung cancer (SCLC) remains one of the most aggressive thoracic malignancies with an especially dismal prognosis. While the detection of various targetable driver mutations and immune checkpoints have revolutionized the treatment of non-small cell lung cancer (NSCLC), there has been only modest therapeutic innovation over the past decades in SCLC. In this review, we aim to provide a brief summary on the clinical relevance of recent research findings, which could soon pave the way towards a more personalized and targeted management of SCLC patients. Recent findings: Substantial research on the biological and molecular heterogeneity of SCLC has been conducted in the last years. Recent results from comprehensive profiling studies have shown that unique major SCLC subtypes can be distinguished based on the relative expression of key transcription regulators (ASCL1, NEUROD1, POU2F3) or distinct inflammatory features. Understanding the differing molecular characteristics of these distinct subtypes has resulted in the identification of specific therapeutic vulnerabilities. Summary: The recently introduced molecular SCLC subtype classification represents a substantial progress towards a personalized and more efficacious approach in SCLC. The consequences of this paradigm shift provide hope for improved patient care and clinical outcomes in this exceptionally lethal thoracic malignancy.
MeSH term(s)	Humans ; Small Cell Lung Carcinoma/genetics ; Small Cell Lung Carcinoma/therapy ; Carcinoma, Non-Small-Cell Lung ; Lung Neoplasms/genetics ; Lung Neoplasms/therapy
Language	English
Publishing date	2023-10-18
Publishing country	United States
Document type	Review ; Journal Article
ZDB-ID	1049384-0
ISSN	1531-703X ; 1040-8746
ISSN (online)	1531-703X
ISSN	1040-8746
DOI	10.1097/CCO.0000000000001005
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3046: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Exhaled Biomarkers for Point-of-Care Diagnosis: Recent Advances and New Challenges in Breathomics.

Kiss, Helga / Örlős, Zoltán / Gellért, Áron / Megyesfalvi, Zsolt / Mikáczó, Angéla / Sárközi, Anna / Vaskó, Attila / Miklós, Zsuzsanna / Horváth, Ildikó

Micromachines

2023 Volume 14, Issue 2

Abstract: Cancers, chronic diseases and respiratory infections are major causes of mortality and present diagnostic and therapeutic challenges for health care. There is an unmet medical need for non-invasive, easy-to-use biomarkers for the early diagnosis, ... ...

Abstract	Cancers, chronic diseases and respiratory infections are major causes of mortality and present diagnostic and therapeutic challenges for health care. There is an unmet medical need for non-invasive, easy-to-use biomarkers for the early diagnosis, phenotyping, predicting and monitoring of the therapeutic responses of these disorders. Exhaled breath sampling is an attractive choice that has gained attention in recent years. Exhaled nitric oxide measurement used as a predictive biomarker of the response to anti-eosinophil therapy in severe asthma has paved the way for other exhaled breath biomarkers. Advances in laser and nanosensor technologies and spectrometry together with widespread use of algorithms and artificial intelligence have facilitated research on volatile organic compounds and artificial olfaction systems to develop new exhaled biomarkers. We aim to provide an overview of the recent advances in and challenges of exhaled biomarker measurements with an emphasis on the applicability of their measurement as a non-invasive, point-of-care diagnostic and monitoring tool.
Language	English
Publishing date	2023-02-04
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2620864-7
ISSN	2072-666X
ISSN	2072-666X
DOI	10.3390/mi14020391
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A molekuláris altípusok szerinti heterogenitás biológiai és klinikai jelentősége kissejtes tüdőrákban.

Berta, Judit / Ferencz, Bence / Horváth, Lilla / Fillinger, János / Lantos, András / Bogos, Krisztina / Rényi-Vámos, Ferenc / Megyesfalvi, Zsolt / Döme, Balázs

Magyar onkologia

2023 Volume 67, Issue 3, Page(s) 181–192

Abstract: Small-cell lung cancer (SCLC) is a highly aggressive malignancy characterised by genomic instability and early metastatic spread. Patients are typically diagnosed at advanced disease stage, when platinum-based chemotherapy with immunotherapy represents ... ...

Title translation	Small cell lung cancer heterogeneity and molecular subtypes: biological and clinical relevance.
Abstract	Small-cell lung cancer (SCLC) is a highly aggressive malignancy characterised by genomic instability and early metastatic spread. Patients are typically diagnosed at advanced disease stage, when platinum-based chemotherapy with immunotherapy represents the standard therapeutic approach. The role of radiotherapy with concomitant systemic therapy is also well established in the management of SCLC patients. Although these therapeutic approaches are initially effective, most patients rapidly develop resistance. This clearly highlights the need to improve therapeutic efficacy and broaden the scope of current therapeutic strategies. Recent advances in the study of this disease, once considered homogeneous, have led to a new model of the SCLC classification scheme based on the relative expression of certain transcriptional regulators and inflammatory characteristics. New biological insights into the molecular subtypes of SCLC could lead to the implementation of subtype-specific therapeutic approaches. Here, we summarise our key findings concerning the biological and clinical relevance of SCLC molecular subtypes.
MeSH term(s)	Humans ; Clinical Relevance ; Small Cell Lung Carcinoma/genetics ; Small Cell Lung Carcinoma/therapy ; Immunotherapy ; Platinum ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics
Chemical Substances	Platinum (49DFR088MY)
Language	Hungarian
Publishing date	2023-08-25
Publishing country	Hungary
Document type	English Abstract ; Journal Article
ZDB-ID	414033-3
ISSN	2060-0399 ; 0025-0244
ISSN (online)	2060-0399
ISSN	0025-0244
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5853: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Small cells - big issues: biological implications and preclinical advancements in small cell lung cancer.

Solta, Anna / Ernhofer, Büsra / Boettiger, Kristiina / Megyesfalvi, Zsolt / Heeke, Simon / Hoda, Mir Alireza / Lang, Christian / Aigner, Clemens / Hirsch, Fred R / Schelch, Karin / Döme, Balazs

Molecular cancer

2024 Volume 23, Issue 1, Page(s) 41

Abstract: Current treatment guidelines refer to small cell lung cancer (SCLC), one of the deadliest human malignancies, as a homogeneous disease. Accordingly, SCLC therapy comprises chemoradiation with or without immunotherapy. Meanwhile, recent studies have made ... ...

Abstract	Current treatment guidelines refer to small cell lung cancer (SCLC), one of the deadliest human malignancies, as a homogeneous disease. Accordingly, SCLC therapy comprises chemoradiation with or without immunotherapy. Meanwhile, recent studies have made significant advances in subclassifying SCLC based on the elevated expression of the transcription factors ASCL1, NEUROD1, and POU2F3, as well as on certain inflammatory characteristics. The role of the transcription regulator YAP1 in defining a unique SCLC subset remains to be established. Although preclinical analyses have described numerous subtype-specific characteristics and vulnerabilities, the so far non-existing clinical subtype distinction may be a contributor to negative clinical trial outcomes. This comprehensive review aims to provide a framework for the development of novel personalized therapeutic approaches by compiling the most recent discoveries achieved by preclinical SCLC research. We highlight the challenges faced due to limited access to patient material as well as the advances accomplished by implementing state-of-the-art models and methodologies.
MeSH term(s)	Humans ; Small Cell Lung Carcinoma/genetics ; Small Cell Lung Carcinoma/therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/therapy ; Immunotherapy ; Transcription Factors
Chemical Substances	Transcription Factors
Language	English
Publishing date	2024-02-24
Publishing country	England
Document type	Journal Article ; Review ; Research Support, Non-U.S. Gov't
ZDB-ID	2091373-4
ISSN	1476-4598 ; 1476-4598
ISSN (online)	1476-4598
ISSN	1476-4598
DOI	10.1186/s12943-024-01953-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Lung squamous cell carcinoma with rare epidermal growth factor receptor mutation G719X: a case report and literature review.

Bi, Huanhuan / Ren, Dunqiang / Wu, Jieqiong / Ding, Xiaoqian / Guo, Caihong / Miura, Satoru / Megyesfalvi, Zsolt / Arulananda, Surein / Wang, Hongmei

Annals of translational medicine

2022 Volume 9, Issue 24, Page(s) 1805

Abstract: Asians who develop non-small cell lung cancer (NSCLC) have a chance of approximately 50% of harboring the epidermal growth factor receptor (EGFR) mutation. The G719X mutation in EGFR has 3 subtypes (i.e., G719A, G719C, or G719S), all of them being ... ...

Abstract	Asians who develop non-small cell lung cancer (NSCLC) have a chance of approximately 50% of harboring the epidermal growth factor receptor (EGFR) mutation. The G719X mutation in EGFR has 3 subtypes (i.e., G719A, G719C, or G719S), all of them being classified as uncommon EGFR mutations. The EGFR mutation G719X is most often associated with lung adenocarcinoma. Conversely, its occurrence in lung squamous cell carcinoma is rare. Its response to tyrosine kinase inhibitor (TKI) treatment remains unknown. A 50-year-old Asian male with no smoking history was admitted to our hospital (Affiliated Hospital of Qingdao University) with an irritating dry cough and 1 month of progressive dyspnea. The patient was diagnosed with lung squamous cell carcinoma (cT4N3M0, stage IIIC). Lung biopsy revealed the presence of EFGR G719X mutation. The patient received a tracheobronchial stent, targeted therapy, chemotherapy, seed implantation and radiotherapy, and survived for 25.4 months following diagnosis. It is crucial that gene mutation analysis is performed in non-smoking male squamous cell carcinoma patients. Compared to lung adenocarcinoma patients with rare G719X mutation, this lung squamous cell carcinoma patient with G719X-mutant tumor had a higher sensitivity to 2
Language	English
Publishing date	2022-01-05
Publishing country	China
Document type	Case Reports
ZDB-ID	2893931-1
ISSN	2305-5847 ; 2305-5839
ISSN (online)	2305-5847
ISSN	2305-5839
DOI	10.21037/atm-21-6653
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: [No title information]

Bogos, Krisztina / Török, Szilvia / Pucsok, Mariann / Cselko, Zsuzsanna / Rényi-Vámos, Ferenc / Ostoros, Gyula / Döme, Balázs / Megyesfalvi, Zsolt

Magyar onkologia

2022 Volume 66, Issue 1, Page(s) 43–49

Abstract: The COVID-19 pandemic has posed significant challenges to healthcare systems worldwide. Patients with cancer, and particularly those with lung malignancies, represent a highrisk group for COVID-19 since they are more susceptible to infection and have a ... ...

Title translation	Covid-19-fertőzés klinikai jelentősége tüdőrák és egyéb malignus mellkasi daganatok esetén.
Abstract	The COVID-19 pandemic has posed significant challenges to healthcare systems worldwide. Patients with cancer, and particularly those with lung malignancies, represent a highrisk group for COVID-19 since they are more susceptible to infection and have a higher risk of severe outcomes. However, the restructuration of the healthcare environment, the development of guidelines for treatment and surveillance, and the improvement of vaccination coverage allowed adequate patient shielding and continuity of oncological care of cancer patients. By shedding light on the characteristics of COVID-19 patients with thoracic malignancies, recent studies also contributed to the development of personalized therapeutic strategies. Accordingly, several determinants were identified to predict disease outcomes. These include the ECOG performance status, the levels of C-reactive protein, neutrophils and procalcitonin, the disease stage, and the presence of pneumonia. COVID-19 vaccines are safe in patients with lung cancer. In order to obtain adequate immunization, the booster dose is recommended in these patients.
MeSH term(s)	Breast Neoplasms ; COVID-19/prevention & control ; COVID-19 Vaccines ; Female ; Humans ; Immunization Programs ; Lung Neoplasms/therapy ; Pandemics/prevention & control
Chemical Substances	COVID-19 Vaccines
Language	Hungarian
Publishing date	2022-02-17
Publishing country	Hungary
Document type	Journal Article
ZDB-ID	414033-3
ISSN	2060-0399 ; 0025-0244
ISSN (online)	2060-0399
ISSN	0025-0244
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5853: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Next-Generation Sequencing May Discriminate Extreme Long-term versus Short-term Survival in Patients with Metastatic Small Cell Lung Cancer (SCLC).

Lohinai, Zoltan / Megyesfalvi, Zsolt / Dome, Balazs / Weiss, Glen J

Translational oncology

2019 Volume 12, Issue 12, Page(s) 1539–1548

Abstract: Background: Molecular underpinnings that may prognosticate survival could increase understanding of small cell lung cancer (SCLC) tumor behavior. Here, we report the clinicopathological characteristics and biomarker profiles of short-term (ST) versus ... ...

Abstract	Background: Molecular underpinnings that may prognosticate survival could increase understanding of small cell lung cancer (SCLC) tumor behavior. Here, we report the clinicopathological characteristics and biomarker profiles of short-term (ST) versus long-term (LT) survival in patients with metastatic SCLC. Methods: Of the 876 consecutive metastatic SCLC patients receiving standard of care therapy, 44 met the definition of LT and 91 for ST, respectively. Available FFPE tumor tissue blocks were analyzed by next-generation sequencing (NGS). Analysis included gene mutations, copy number variations, mRNA expression, and protein expression by immunohistochemistry, followed by correlation with clinicopathological characteristics. Results: There were no statistically significant and clinically relevant differences in cases with or without FFPE according to major clinicopathological variables in ST and LT. However, according to NGS, five mutually exclusive gene mutations were identified (E1A binding protein P300 [EP300] p.N217S; p.E152K; human epidermal growth factor receptor 4 [ERBB4] p.E317K; BRCA1, DNA repair associated [BRCA1] p.E1661N, and epidermal growth factor receptor [EGFR] p.V742A). Comparing LT vs. ST survivals, a twofold increase was found in the average predicted number of drugs per patient off compendium. We found high SSTR2 mRNA expressions in all LT patients (vs. two [20%] ST patients), which may reflect more benign neuroendocrine tumor characteristics. Conclusions: Consolidation radiation therapy and higher predicted drug sensitivity for off compendium were associated with LT compared to ST patients in SCLC. NGS profiling of extreme survivals may improve classification of SCLC and possibly identify clinically relevant new targets.
Language	English
Publishing date	2019-08-31
Publishing country	United States
Document type	Journal Article
ZDB-ID	2443840-6
ISSN	1936-5233 ; 1936-5233 ; 1944-7124
ISSN (online)	1936-5233
ISSN	1936-5233 ; 1944-7124
DOI	10.1016/j.tranon.2019.08.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Computed Tomography-Based Quantitative Texture Analysis and Gut Microbial Community Signatures Predict Survival in Non-Small Cell Lung Cancer.

Dora, David / Weiss, Glen J / Megyesfalvi, Zsolt / Gállfy, Gabriella / Dulka, Edit / Kerpel-Fronius, Anna / Berta, Judit / Moldvay, Judit / Dome, Balazs / Lohinai, Zoltan

Cancers

2023 Volume 15, Issue 20

Abstract: This study aims to combine computed tomography (CT)-based texture analysis (QTA) and a microbiome-based biomarker signature to predict the overall survival (OS) of immune checkpoint inhibitor (ICI)-treated non-small cell lung cancer (NSCLC) patients by ... ...

Abstract	This study aims to combine computed tomography (CT)-based texture analysis (QTA) and a microbiome-based biomarker signature to predict the overall survival (OS) of immune checkpoint inhibitor (ICI)-treated non-small cell lung cancer (NSCLC) patients by analyzing their CT scans (
Language	English
Publishing date	2023-10-21
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers15205091
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status.

Dora, David / Ligeti, Balazs / Kovacs, Tamas / Revisnyei, Peter / Galffy, Gabriella / Dulka, Edit / Krizsán, Dániel / Kalcsevszki, Regina / Megyesfalvi, Zsolt / Dome, Balazs / Weiss, Glen J / Lohinai, Zoltan

Oncoimmunology

2023 Volume 12, Issue 1, Page(s) 2204746

Abstract: Due to the high variance in response rates concerning anti-PD1 immunotherapy (IT), there is an unmet need to discover innovative biomarkers to predict immune checkpoint inhibitor (ICI)-efficacy. Our study included 62 Caucasian advanced-stage non-small ... ...

Abstract	Due to the high variance in response rates concerning anti-PD1 immunotherapy (IT), there is an unmet need to discover innovative biomarkers to predict immune checkpoint inhibitor (ICI)-efficacy. Our study included 62 Caucasian advanced-stage non-small cell lung cancer (NSCLC) patients treated with anti-PD1 ICI. Gut bacterial signatures were evaluated by metagenomic sequencing and correlated with progression-free survival (PFS), PD-L1 expression and other clinicopathological parameters. We confirmed the predictive role of PFS-related key bacteria with multivariate statistical models (Lasso- and Cox-regression) and validated on an additional patient cohort (
MeSH term(s)	Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/pathology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Progression-Free Survival ; B7-H1 Antigen ; Antineoplastic Agents, Immunological/adverse effects ; Immunotherapy ; Metabolic Networks and Pathways
Chemical Substances	B7-H1 Antigen ; Antineoplastic Agents, Immunological
Language	English
Publishing date	2023-05-12
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2645309-5
ISSN	2162-402X ; 2162-402X
ISSN (online)	2162-402X
ISSN	2162-402X
DOI	10.1080/2162402X.2023.2204746
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito